Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 296-305

  Dickinson, Laura ^a   Khoo, Saye ^a   Back, David ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Healthy volunteers; HIV; Pharmacokinetics; Protease inhibitors

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; KETOCONAZOLE; LOPINAVIR; OMEPRAZOLE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

DRUG BLOOD LEVEL; DRUG DISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 42049111191     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f82bf1     Document Type: Review

References (71)

1. Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2000; 60:865-873.
2. Slain D, Pakyz A, Israel DS, et al. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000; 20:898-907.
3. Welage LS, Carver PL, Revankar S, et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1431-1438.
4. Merry C, Mulcahy F, Lloyd J, et al. Alpha-1-acid glycoprotein concentrations in HIV disease. Implications for treatment with protease inhibitors. AIDS 1996; 10:21.
5. Bristol-Myers Squibb Co.: Reyataz® (atazanavir): product information. Princeton, New Jersey, USA: Bristol-Myers Squibb Co.; 2007.
6. Le Tiec C, Barrail A, Goujard C, et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44:1035-1050.
7. Guiard-Schmid JB, Poirier JM, Bonnard P, et al. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS 2005; 19:1937-1938.
8. von Hentig N, Dauer B, Haberl A, et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol 2007; 63:935-940.
9. von Hentig N, Muller A, Rottmann C, et al. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 2007; 51:1431-1439.
10. Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006; 11:421-429.
11. Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006; 20:1131-1139.
12. Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther 2006; 11:53-62.
13. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
14. Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of oncedaily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007; 8:457-464.
15. Pham PA, Flexner C, Parsons T, et al. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. J Acquir Immune Defic Syndr 2007; 45:201-205.
16. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007; 91:269-278.
17. Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336-3342.
18. th European AIDS Conference (EACS); 24-27 October 2007; Madrid, Spain. Paris, France: European AIDS Clinical Society; 2007.
19. Waters LJ, Moyle G, Bonora S, et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12:825-830.
20. Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829:82-90.
21. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410.
22. Jassen-Cilag Ltd: Prezista® (darunavir ethanolate) 300 mg film-coated tablets: summary of product characteristics. Wycomb, Buckinghamshire, UK: Jassen-Cilag Ltd; 2007.
23. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46:739-756.
24. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449-1455.
25. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12:789-796.
26. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother 2007; 51:958-961.
27. Oie S, Jacobson MA, Abrams DI. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993; 6:531-533.
28. th European AIDS Conference (EACS); 24-27 October 2007; Madrid, Spain. Paris, France: European AIDS Clinical Society; 2007.
29. th Annual Meeting of the Population Approach Group in Europe (PAGE). 14-16 June 2006. Bruges, Belgium. June 2006 [Abstract 964] 2006. Paris, France: PAGE; 2006. http://www.page-meeting.org/? abstract=964 [Accessed 13 February 2008].
30. GlaxoSmithKline UK: Telzir® (fosamprenavir calcium) 700 mg film-coated tablets: summary of product characteristics. Brentford, Middlesex, UK: Glaxo-SmithKline UK; 2007.
31. Kim YH, Hu C, Wire MB, et al. Steady-state amprenavir pharmacokinetics are similar between healthy and HIV-infected subjects following GW433908 ± ritonavir using population pharmacokinetic analysis [abstract 7.5]. In: Program and Abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; 1-3 April 2004; Rome, Italy. Geneva, Switzerland: International AIDS Society; 2004.
32. Seminari E, De Bona A, Gentilini G, et al. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. J Antimicrob Chemother 2007; 60:831-836.
33. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45:137-168.
34. Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19:145-152.
35. Wire MB, Ballow CH, Borland J, et al. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. Antimicrob Agents Chemother 2007; 51:2982-2984.
36. Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother 2007; 51:560-565.
37. Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006; 42:61-67.
38. Wire MB, Ballow C, Preston SL, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004; 18:897-907.
39. Abbott Laboratories Limited: Kaletra® (lopinavir/ritonavir) 133.3/33.3 mg soft capsules: summary of product characteristics. Abbott Park, Illinois, USA: Abbott Laboratories Limited; 2007.
40. Abbott Laboratories Limited: Kaletra® (lopinavir/ritonavir) 200/50 mg film-coated tablets: summary of product characteristics. Abbott Park, Illinois, USA: Abbott Laboratories Limited; 2007.
41. Molto J, Valle M, Blanco A, et al. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis. Clin Pharmacokinet 2007; 46:85-92.
42. von Hentig N, Muller A, Rottmann C, et al. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. Eur J Med Res 2006; 11:236-244.
43. Dicenzo R, Luque A, Larppanichpoonphol P, et al. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. J Antimicrob Chemother 2006; 58:393-400.
44. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002; 3:304-309.
45. Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007; 81:69-75.
46. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006; 43 (suppl 4):S235-S246.
47. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43:278-283.
48. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004; 36:1034-1040.
49. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
50. Roche Pharmaceuticals: Invirase® (saquinavir mesylate) capsules and tablets: US prescribing information. Nutley, New Jersey, USA: Roche Pharmaceuticals; 2007.
51. Dickinson L, Back D, Winston A, et al. Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500 mg film-coated tablets (1000/100 mg twice daily) [abstract 60]. In: Program and Abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon, Portugal. Geneva, Switzerland: International AIDS Society; 2006.
52. Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001; 57:115-121.
53. ••].
54. max were 82%, 106% and 75%, respectively).
55. Lotsch J, Harder S, Sturmer M, et al. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007; 51:3264-3272.
56. Stocker H, Herzmann C, Breske A, et al. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration. J Antimicrob Chemother 2007; 59:560-564.
57. Boffito M, Maitland D, Dickinson L, et al. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother 2005; 55:542-545.
58. Boffito M, Back D, Stainsby-Tron M, et al. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol 2005; 59:38-42.
59. King JR, Kakuda TN, Paul S, et al. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol 2007; 47:201-208.
60. Chittick GE, Zong J, Blum MR, et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 2006; 50:1304-1310.
61. Kurowski M, Sternfeld T, Sawyer A, et al. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003; 4:94-100.
62. Boehringer Ingelheim Limited: Aptivus® (tipranavir) 250 mg soft capsules: summary of product characteristics. Ridgefield, Connecticut, USA: Boehringer Ingelheim Limited; 2007.
63. Boehringer Ingelheim Pharmaceuticals: Aptivus® (tipranavir) capsules: US prescribing information. Ridgefield, Connecticut, USA: Boehringer Ingelheim Limited; 2007.
64. th Conference on Retroviruses and Opportunistic Infections (CROI); 22-25 February 2005; Boston, Massachusetts, USA. Alexandria, Virginia, USA: CROI; 2005. http://www.aegis.com/conferences/croi/2005/654.html [Accessed 13 February 2008].
65. Sabo JP, Yong CL, MacGregor TR, et al. Nonlinear mixed effects modeling of the steady-state pharmacokinetics of tipranavir for adult healthy volunteers and HIV+ patients receiving TPV 500 mg bid coadministered with RTV 100 mg or 200 mg bid [abstract 7]. In: Program and Abstracts of the 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest, Hungary. Geneva, Switzerland: International AIDS Society; 2007.
66. Bonora S, D'Avolio A, Gonzalez de Requena D, et al. Intracellular accumulation of tipranavir/ritonavir in the clinical setting [abstract 48]. In: Program and Abstracts of the 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest, Hungary. Geneva, Switzerland: International AIDS Society; 2007.
67. Gonzalez de Requena D, Calcagno A, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006; 20:1977-1979.
68. Curran A, Lopez R, Pou L, et al. Pharmacokinetic evaluation of potential interaction between tipranavir and enfuvirtide [abstract 53]. In: Program and Abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon, Portugal. Geneva, Switzerland: International AIDS Society; 2006.
69. Chen L, Sabo JP, Philip E, et al. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. Antimicrob Agents Chemother 2007; 51:2436-2444.
70. la Porte CJ, Cameron DW, Sabo JP, et al. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir coadministered with ritonavir [abstract 59]. In: Program and Abstracts of the 8th International Workshop on Clinical Pharmacology of HIV Therapy; 16-18 April 2007; Budapest, Hungary. Geneva, Switzerland: International AIDS Society; 2007.
71. MacGregor TR, Sabo JP, Norris SH, et al. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 2004; 5:371-382.